MedTrace Logo

Safety, Tolerability, Pharmacokinetics and Antiviral Activity of GS-9669 in Subjects With Chronic Hepatitis C Virus Infection

NCT01431898 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 82

Last updated 2012-07-25

No results posted yet for this study

Summary

This is a research study to evaluate the safety, tolerability and anti-viral activity of GS-9669 in patients with Hepatitis C infection.

Conditions

  • Hepatitis C

Interventions

DRUG

GS-9669 tablets

DRUG

Placebo to Match GS-9669 tablet

Sponsors & Collaborators

Principal Investigators

  • Stephen Rossi, PharmD · Gilead Sciences

Study Design

Purpose
TREATMENT
Masking
SINGLE

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-09-30
Primary Completion
2011-12-31
Completion
2012-05-31

Countries

  • United States
  • Puerto Rico

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01431898 on ClinicalTrials.gov